Evidence map›Paper›PMID 35941959›Full record

ArticleJournal of the Chinese Chemical Society. Zhongguo hua xue hui (Taipei, Taiwan)2022

Synthesis, crystal structure elucidation, DFT analysis, drug-likeness and ADMET evaluation and molecular docking studies of triazole derivatives: Binary inhibition of spike protein and ACE2 receptor protein of COVID-19.

Saminathan Murugavel, Perumal Vasudevan, RaviKumar Chandrasekaran, Vellingiri Archana, Alagusundaram Ponnuswany

Abstract read
In one paragraph

Article in Journal of the Chinese Chemical Society. Zhongguo hua xue hui (Taipei, Taiwan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Saminathan MurugavelDepartment of Physics Thanthai Periyar Government Institute of Technology Vellore Tamil Nadu India.ORCID https://orcid.org/0000-0002-4626-8104
Perumal VasudevanDepartment of Physics Thanthai Periyar Government Institute of Technology Vellore Tamil Nadu India.
RaviKumar ChandrasekaranDepartment of Physics Thanthai Periyar EVR Government Polytechnic College Vellore Tamil Nadu India.ORCID https://orcid.org/0000-0001-6981-5142
Vellingiri ArchanaDepartment of Chemistry School of Physical Sciences and Computational Sciences, Avinashilingam Institute for Home Science and Higher Education for Women Coimbatore Tamil Nadu India.
Alagusundaram PonnuswanyDepartment of Organic chemistry School of chemistry, Madurai Kamaraj University Madurai Tamil Nadu India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent incidence of terrible acute respiratory syndrome coronavirus 2 (SARS CoV-2) has presently experienced some noteworthy mutations since its discovery in 2019 in Wuhan, China. The present research work focuses on the synthesis of three triazole derivatives (BMTPP, BMTTP, and BMTIP) and their inhibition activities against SARS-Cov-2 spike and ACE2 receptor proteins. The crystal structure for BMTTP was determined by the SCXRD method and optimized geometrical parameters for the three triazole derivatives were obtained by DFT calculations. HOMO-LUMO, Global reactive descriptors [GRD], and Molecular electrostatic potential (MEP) investigations exposed that all three compounds have biological properties. The drug-likeness ability of the synthesized compounds was examined using Molinspiration and a pre-ADMET online Server. Further, to explore the binding nature of three synthesized compounds with SARS-Cov-2 spike proteins/ACE2 receptor molecular docking studies were executed. The outcomes we obtained from molecular docking simulation studies suggest that the synthesized triazole derivatives may be well utilized as curing medicines against COVID-19. Ultimately, animal tests and precise clinical tests are required to prove the potent nature of these compounds against COVID-19. Finally, the present outcomes must be proved to utilize in-vitro and in-vivo antiviral methods.

Indexed as

ADMETCOVID‐19crystal structureDFTdockingdrug‐likenesstriazole

Identifiers

PMID35941959
PMCPMC9347919

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.